Fragile X Syndrome – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the total prevalence of FXS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
DRG Epidemiology’s FXS forecast will answer the following questions
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FXS over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts the following FXS patient population:
Fragile X Syndrome - Epidemiology - Mature Markets
Introduction
Abstract
Key Findings
Key Updates
Prevalence of Fragile X Syndrome per 100,000 People of All Ages in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Fragile X Syndrome over the Next 20 Yearsttttttttt
Epidemiology Data
Methods
Total Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Fragile X Syndrome
Studies Excluded from the Analysis of Fragile X Syndrome
Risk/Protective Factors
Risk/Protective Factors for Fragile X Syndrome
Bibliography
Glossary
Latashree Goswami
Latashree Goswami, M.P.H.,is an associate epidemiologist at Clarivate. She holds an M.P.H. from the Indian Institute of Public Health where she specialized in health economics, financing, and policy, and a B.D.S. from India’s ITS Dental College.
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
